These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33372679)

  • 1. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
    Samaei A; Moradi K; Bagheri S; Ashraf-Ganjouei A; Alikhani R; Mousavi SB; Rezaei F; Akhondzadeh S
    Int J Neuropsychopharmacol; 2020 Dec; 23(12):775-782. PubMed ID: 33372679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
    Salehi A; Namaei P; TaghaviZanjani F; Bagheri S; Moradi K; Khodaei Ardakani MR; Akhondzadeh S
    Psychiatry Res; 2022 Oct; 316():114737. PubMed ID: 35917650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Khoaie-Ardakani MR; Shahmoradi Z; Alavi AR; Afarideh M; Shalbafan MR; Ghazizadeh-Hashemi M; Akhondzadeh S
    Psychiatry Res; 2018 Apr; 262():94-101. PubMed ID: 29427913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
    Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
    Noroozian M; Ghasemi S; Hosseini SM; Modabbernia A; Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Rezaei F; Salehi B; Ashrafi M; Yekehtaz H; Tabrizi M; Akhondzadeh S
    Psychopharmacology (Berl); 2013 Aug; 228(4):595-602. PubMed ID: 23515583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Hosseini SM; Modabbernia A; Rezaei F; Salehi B; Yekehtaz H; Ashrafi M; Tabrizi M; Akhondzadeh S
    Psychiatry Res; 2014 Mar; 215(3):540-6. PubMed ID: 24480077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.
    Kashani L; Shams N; Moazen-Zadeh E; Karkhaneh-Yousefi MA; Sadighi G; Khodaie-Ardakani MR; Rezaei F; Rahiminejad F; Akhondzadeh S
    J Psychiatr Res; 2017 Nov; 94():70-77. PubMed ID: 28688338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial.
    Hendouei F; Sanjari Moghaddam H; Mohammadi MR; Taslimi N; Rezaei F; Akhondzadeh S
    J Clin Pharm Ther; 2020 Apr; 45(2):324-334. PubMed ID: 31714621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
    Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S
    Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.
    Tajik-Esmaeeli S; Moazen-Zadeh E; Abbasi N; Shariat SV; Rezaei F; Salehi B; Akhondzadeh S
    Int Clin Psychopharmacol; 2017 Mar; 32(2):87-94. PubMed ID: 27941358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
    Harvey PD; Nakamura H; Miura S
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.